In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Genzyme's tender offer for Bioenvision

Executive Summary

In an effort to strengthen its oncology business, Genzyme has agreed to acquire all outstanding common shares of Bioenvision (cancer therapies) for $5.60 each (a 36% premium) and all outstanding Series A convertible preferred shares for $11.20; total transaction value would be $345mm.
Deal Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Contract
    • Payment Includes Cash
    • Intra-Biotech Deal
    • Full Acquisition

Related Companies

Advertisement
UsernamePublicRestriction

Register